Cargando…

Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations

Knowledge of the involvement of the neurokinin substance P in emesis has led to the development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of chemotherapy-induced nausea and vomiting (CINV), in combination with serotonin type 3 receptor antagonists and corticosteroids. The NK-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rapoport, Bernardo Leon, Aapro, Matti, Chasen, Martin R, Jordan, Karin, Navari, Rudolph M, Schnadig, Ian, Schwartzberg, Lee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592904/ https://www.ncbi.nlm.nih.gov/pubmed/28919712 http://dx.doi.org/10.2147/DDDT.S133943

Ejemplares similares

Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy
por: Chasen, Martin, et al.
Publicado: (2016)

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy
por: Hesketh, Paul J., et al.
Publicado: (2016)

Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting
por: Rapoport, Bernardo Leon
Publicado: (2017)

Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy
por: Navari, Rudolph M., et al.
Publicado: (2018)

Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
por: Barbour, S., et al.
Publicado: (2017)

Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
por: Rashad, Noha, et al.
Publicado: (2017)

Morphological and Skeletal Abnormalities Induced by Rolapitant: An Antiemetic Agent
por: Solanki, Sohel, et al.
Publicado: (2022)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Safety of Polysorbate 80 in the Oncology Setting
por: Schwartzberg, Lee S., et al.
Publicado: (2018)

Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018)

A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting
por: Hesketh, Paul J., et al.
Publicado: (2015)

Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study
por: Bonjoch, Anna, et al.
Publicado: (2016)

Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2()
por: Hortobagyi, Gabriel N.
Publicado: (2015)

Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study
por: Rapoport, Bernardo Leon, et al.
Publicado: (2018)

Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study
por: Samukawa, Yoshishige, et al.
Publicado: (2016)

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Baron-Hay, Sally, et al.
Publicado: (2019)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
por: Escudier, B, et al.
Publicado: (2014)

Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
por: Kohsaka, Shun, et al.
Publicado: (2020)

Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature
por: Chow, Ronald, et al.
Publicado: (2021)

Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses
por: Kjeldsen, Sverre E., et al.
Publicado: (2016)

Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study
por: Terpos, Evangelos, et al.
Publicado: (2020)

Recent advances, patient selection & challenges in managing cancer patients undergoing treatment with immune checkpoint inhibitors
por: Rapoport, Bernardo Leon, et al.
Publicado: (2022)

Frontiers in Pharmacology: Review Manuscript Targeting of the Neutrophil as an Adjunctive Strategy in Non-Small Cell Lung Cancer
por: Anderson, Ronald, et al.
Publicado: (2021)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

Palonosetron as an anti-emetic and anti-nausea agent in oncology
por: Aapro, Matti S
Publicado: (2007)

SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly
por: Aapro, Matti
Publicado: (2011)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts
por: Aapro, Matti
Publicado: (2018)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—introduction
por: Aapro, Matti
Publicado: (2018)

CINV: still troubling patients after all these years
por: Aapro, Matti
Publicado: (2018)

The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer
por: Aapro, Matti
Publicado: (2017)

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy
por: Navari, Rudolph M
Publicado: (2009)

Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
por: Navari, Rudolph M.
Publicado: (2015)

Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
por: Navari, Rudolph M
Publicado: (2014)

The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
por: Dranitsaris, G., et al.
Publicado: (2017)

Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors
por: Rapoport, Bernardo Leon
Publicado: (2019)

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial
por: Schnadig, Ian D, et al.
Publicado: (2017)

Getting it right the first time: recent progress in optimizing antiemetic usage
por: Schwartzberg, Lee
Publicado: (2018)

Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy
por: Navari, Rudolph M, et al.
Publicado: (2019)

Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
por: Chen, Clara, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uq267mljvqohnkavtat1h2ju4p